The Relative Strength (RS) Rating for Viridian Therapeutics entered a higher percentile Friday, as it got a lift from 62 to 71.
IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the top-performing stocks often have an RS Rating north of 80 as they launch their biggest runs. See if Viridian Therapeutics can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Viridian Therapeutics has climbed more than 5% past an 18.27 entry in a first-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Viridian Therapeutics showed 0% EPS growth in the latest quarterly report. Revenue increased 29%.
The company holds the No. 224 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
